The researchers of The University of Manchester demonstrated a new class of drugs that can stop the growth of ovarian cancer cells.
The research was published in the journal Cancer Cell on March 18, 2019. This study highlights the drugs, called PARG-inhibitors. This drug has the capability to kill ovarian cancer cells. It targets the cells which have the ability to copy their DNA.
According to the reports, the researchers have discovered this new class PARG inhibitor PDD00017273 in the Drug Discovery Unit at the Cancer Research UK Manchester Institute.
For the research, scientists were able to detect ovarian cancer cells for specific genes. When these genes are knocked out they make cancer cells sensitive to PARG-inhibitor. This further help in the killing of these cancer cells.
Scientists also recognized those genes that made cancer cell sensitive to PDDD0017273 which were involved in making DNA copies. According to scientists, this research will prove promising for those women who are being diagnosed with ovarian cancer.
This research was done with the collaboration with IDEAYA Bioscience, Inc, an oncology-focused biotechnology company.
Prof Stephen Taylor, the study lead and a professor at The University of Manchester, said,“Sadly, for the majority of women diagnosed with ovarian cancer, the cancer relapses within 12 to 18 months of their first treatment, and so there is a pressing need to develop new therapies to treat this condition”.
Nisha Pillay, a PhD student, and another study author, said, “Before a cell divides, it must replicate its DNA. This critical process ensures the necessary amount of DNA is passed on to its daughter cells. Our research has shown that an inherent defect in the ability of an ovarian cancer cell to replicate its DNA can be exploited by the PARG inhibitor to kill the cancer cell”.
Additionally, she said, “This new class of drugs is potentially very exciting and could signal a new way to help patients diagnosed with ovarian cancer in which their tumor has not responded to standard treatments”.
Ovarian cancer is the sixth commonest cause for death in the UK and US. Every year more than 4000 women die from this cancer in the UK. While in the US every year 20,000 women are diagnosed with ovarian cancer.
According to the researchers, the PARG inhibitor can also be used in the combination of CHK1, WEE1 inhibitors and others clinically available drugs to kill the ovarian cancer cells.
With further research, scientists may be able to advance the use of PARG inhibitors for use in the human trail. Also, the scientist may develop biomarkers to chose patients who can be beneficial from this treatment.